Resources from the same session
Optimising patient outcomes with adjuvant Osimertinib: Improving patient identification through non-smoking related NSCLC screening and EGFR reflex testing
Presenter: Fan Yang
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast
Panel discussion: what outcomes should we expect in early stage NSCLC: the importance of targeting the right patients with the right treatment
Presenter: Helena A. Yu
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast
Shaping first-line clinical practice with third-generation EGFR-TKIs in patients with metastatic EGFRm NSCLC
Presenter: Helena A. Yu
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast
Panel discussion: Learnings from real-world practice in first-line metastatic EGFRm NSCLC
Presenter: Helena A. Yu
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast
Meeting close
Presenter: Egbert F. Smit
Session: AstraZeneca - Osimertinib in early- and late-stage NSCLC: Breaking new ground in EGFRm disease
Resources:
Webcast